The estimated Net Worth of Jeffrey S Farrow is at least $9.42 Million dollars as of 17 June 2024. Mr. Farrow owns over 27,881 units of Global Blood Therapeutics stock worth over $1,957,513 and over the last 8 years he sold GBT stock worth over $4,297,524. In addition, he makes $3,168,410 as Chief Financial Officer at Global Blood Therapeutics.
Jeffrey has made over 15 trades of the Global Blood Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 27,881 units of GBT stock worth $1,909,570 on 17 June 2024.
The largest trade he's ever made was selling 31,441 units of Global Blood Therapeutics stock on 1 September 2022 worth over $2,137,988. On average, Jeffrey trades about 5,762 units every 63 days since 2017. As of 17 June 2024 he still owns at least 28,581 units of Global Blood Therapeutics stock.
You can see the complete history of Mr. Farrow stock trades at the bottom of the page.
Jeffrey S. Farrow serves as Chief Financial Officer of the Company. Mr. Farrow previously served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015. Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 where he was part of the team responsible for the successful regulatory approval and commercial launch of RAVICTI® for the treatment of urea cycle disorders. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive).
As the Chief Financial Officer of Global Blood Therapeutics, the total compensation of Jeffrey Farrow at Global Blood Therapeutics is $3,168,410. There are 5 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
Jeffrey Farrow is 58, he's been the Chief Financial Officer of Global Blood Therapeutics since 2016. There are 14 older and 6 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE, CA, 92618.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third..., and Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: